+253.9%
UMC vs GSK
+47.2%
+206.7%
-37.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.5% | -1.0% | -1.5% | -2.6% |
| 7D | +11.4% | -5.4% | +16.8% | +11.2% |
| 30D | +16.8% | -4.6% | +21.4% | +16.6% |
| 3M | +19.1% | -5.1% | +24.2% | +18.7% |
| 6M | +137.4% | -11.4% | +148.9% | +137.3% |
| YTD | +186.4% | +0.7% | +185.7% | +183.5% |
| 1Y | +229.1% | +23.0% | +206.1% | +219.3% |
| All | +253.9% | +47.2% | +206.7% | +242.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling